• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Trump Administration Is Ending Multiple HIV Vaccine Studies, Scientists and Officials Say

June 3, 2025
in Medical Research
Reading Time: 4 mins read
A A
0
4
SHARES
9
VIEWS
Share on FacebookShare on Twitter


Céline Gounder and Alexander Tin, CBS News

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are enough to counter the virus, several scientists and federal health officials say.

This story originally ran on CBS News.

It may not be republished.

Notifications that the funding would not be extended were relayed May 30 to researchers, who were told by National Institutes of Health officials that the Department of Health and Human Services had elected “to go with currently available approaches to eliminate HIV” instead.

The cuts will shutter two major HIV vaccine research efforts first funded by the NIH in 2012 at the Duke Human Vaccine Institute and the Scripps Research Institute, scientists said. A Moderna spokesperson said the vaccine manufacturer’s clinical trials through the NIH’s HIV Vaccine Trials Network have also been put on pause.

One senior NIH official said the HHS had instructed the agency not to issue any more funding in the next fiscal year for HIV vaccine research, with only a handful of exceptions. 

A budgetary rule change specifically targeted at HIV vaccine research is also expected to lead to another cut to the NIH’s awards for studies initiated by scientists, an official said.

The change, to be finalized shortly, inflates the accounting for the upfront cost of studies into HIV vaccines funded by the agency. Instead of the cost of a five-year grant being spread over five years, the NIH plans to make HIV vaccine dollars from multiyear grants all count toward a single year, the official said, making it harder for them to get funded.

A spokesperson for HHS told CBS News that “complex and duplicative health programs have resulted in serious duplication of efforts,” saying that “27 separate programs that address HIV/AIDS” had spent $7.5 billion.

“The Administration believes the United States should have the best medical research in the world. To that end, we are advancing policies to maximize the impact of every federal taxpayer dollar and ensure proper oversight of this funding,” HHS spokesperson Emily Hilliard said.

Hilliard claimed “critical HIV/AIDS programs will continue” under the new agency that Health and Human Services Secretary Robert F. Kennedy Jr. has proposed creating, dubbed the Administration for a Healthy America.

“For HIV vaccine design and development, we’ve begun to see light at the end of the tunnel after many years of research. This is a terrible time to cut it off. We’re beginning to get close. We’re getting good results out of clinical trials,” said Dennis Burton, an immunology professor at Scripps Research.

Burton warned that his institution’s HIV vaccine research could not simply be turned back on, even if a future administration decided to change course on HIV funding. He said that ongoing experiments would be shuttered and that researchers assembled to study the issue would be forced to refocus their careers on other topics.

“This is a decision with consequences that will linger. This is a setback of probably a decade for HIV vaccine research,” Burton said.

The cancellation of the funds comes weeks ahead of the FDA’s June 19 deadline for deciding on approval of lenacapavir, a twice-yearly injectable drug to prevent HIV.

The drug, which is being brought to the commercial market by drugmaker Gilead Sciences, builds on NIH-backed research into earlier HIV medications. The drug’s availability could lead to a significant drop in HIV cases worldwide, since a study found it was 100% effective in preventing transmission.

An NIH official, who was not authorized to speak publicly, rebuked the claim that the effectiveness of current HIV prevention strategies meant a vaccine was no longer needed. “The only way of ending the HIV epidemic in the U.S. and AIDS pandemic worldwide” is with a vaccine, the official said.

Developing an effective HIV vaccine has been an elusive target for researchers, though scientists have hailed recent breakthroughs in the field.

“HIV has established roadblocks to us fighting it off, which are unparalleled in vaccinology. We’ve had to learn what each of the roadblocks are and to devise ways to overcome it. This virus mutates so quickly,” said Duke professor of medicine Barton Ford Haynes, who is part of the Duke Human Vaccine Institute.

Haynes said his institute’s work was essentially combining different vaccines as part of a strategy to design an effective HIV vaccine.

He praised lenacapavir as a “wonderful development for the field” but said there was still a need for a vaccine. Lenacapavir requires injections every six months to remain effective, a challenging proposition even before steep cuts to the Centers for Disease Control and Prevention’s domestic HIV programs and U.S.-backed HIV/AIDS foreign aid programs.

“The hope was that adding an HIV vaccine to all the preventive measures that we have would finally allow us to end the pandemic,” Haynes said.



Céline Gounder and Alexander Tin, CBS News

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are enough to counter the virus, several scientists and federal health officials say.

This story originally ran on CBS News.

It may not be republished.

Notifications that the funding would not be extended were relayed May 30 to researchers, who were told by National Institutes of Health officials that the Department of Health and Human Services had elected “to go with currently available approaches to eliminate HIV” instead.

The cuts will shutter two major HIV vaccine research efforts first funded by the NIH in 2012 at the Duke Human Vaccine Institute and the Scripps Research Institute, scientists said. A Moderna spokesperson said the vaccine manufacturer’s clinical trials through the NIH’s HIV Vaccine Trials Network have also been put on pause.

One senior NIH official said the HHS had instructed the agency not to issue any more funding in the next fiscal year for HIV vaccine research, with only a handful of exceptions. 

A budgetary rule change specifically targeted at HIV vaccine research is also expected to lead to another cut to the NIH’s awards for studies initiated by scientists, an official said.

The change, to be finalized shortly, inflates the accounting for the upfront cost of studies into HIV vaccines funded by the agency. Instead of the cost of a five-year grant being spread over five years, the NIH plans to make HIV vaccine dollars from multiyear grants all count toward a single year, the official said, making it harder for them to get funded.

A spokesperson for HHS told CBS News that “complex and duplicative health programs have resulted in serious duplication of efforts,” saying that “27 separate programs that address HIV/AIDS” had spent $7.5 billion.

“The Administration believes the United States should have the best medical research in the world. To that end, we are advancing policies to maximize the impact of every federal taxpayer dollar and ensure proper oversight of this funding,” HHS spokesperson Emily Hilliard said.

Hilliard claimed “critical HIV/AIDS programs will continue” under the new agency that Health and Human Services Secretary Robert F. Kennedy Jr. has proposed creating, dubbed the Administration for a Healthy America.

“For HIV vaccine design and development, we’ve begun to see light at the end of the tunnel after many years of research. This is a terrible time to cut it off. We’re beginning to get close. We’re getting good results out of clinical trials,” said Dennis Burton, an immunology professor at Scripps Research.

Burton warned that his institution’s HIV vaccine research could not simply be turned back on, even if a future administration decided to change course on HIV funding. He said that ongoing experiments would be shuttered and that researchers assembled to study the issue would be forced to refocus their careers on other topics.

“This is a decision with consequences that will linger. This is a setback of probably a decade for HIV vaccine research,” Burton said.

The cancellation of the funds comes weeks ahead of the FDA’s June 19 deadline for deciding on approval of lenacapavir, a twice-yearly injectable drug to prevent HIV.

The drug, which is being brought to the commercial market by drugmaker Gilead Sciences, builds on NIH-backed research into earlier HIV medications. The drug’s availability could lead to a significant drop in HIV cases worldwide, since a study found it was 100% effective in preventing transmission.

An NIH official, who was not authorized to speak publicly, rebuked the claim that the effectiveness of current HIV prevention strategies meant a vaccine was no longer needed. “The only way of ending the HIV epidemic in the U.S. and AIDS pandemic worldwide” is with a vaccine, the official said.

Developing an effective HIV vaccine has been an elusive target for researchers, though scientists have hailed recent breakthroughs in the field.

“HIV has established roadblocks to us fighting it off, which are unparalleled in vaccinology. We’ve had to learn what each of the roadblocks are and to devise ways to overcome it. This virus mutates so quickly,” said Duke professor of medicine Barton Ford Haynes, who is part of the Duke Human Vaccine Institute.

Haynes said his institute’s work was essentially combining different vaccines as part of a strategy to design an effective HIV vaccine.

He praised lenacapavir as a “wonderful development for the field” but said there was still a need for a vaccine. Lenacapavir requires injections every six months to remain effective, a challenging proposition even before steep cuts to the Centers for Disease Control and Prevention’s domestic HIV programs and U.S.-backed HIV/AIDS foreign aid programs.

“The hope was that adding an HIV vaccine to all the preventive measures that we have would finally allow us to end the pandemic,” Haynes said.


Previous Post

Australian woman accused of triple mushroom murders breaks down in court

Next Post

Sustainable brewing technology and its effectiveness

Related Posts

fatty liver disease

Diabetes drug shows benefits for patients with liver disease

June 5, 2025
1
pregnant

Antibiotics taken during pregnancy may reduce preterm births

June 4, 2025
1
Next Post
Sustainable brewing technology and its effectiveness

Sustainable brewing technology and its effectiveness

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
15-year-old, pinned by car, is killed at SoCal high school

15-year-old, pinned by car, is killed at SoCal high school

June 5, 2025
Harvard foreign student visas targeted in Trump administration proclamation

Harvard foreign student visas targeted in Trump administration proclamation

June 5, 2025
Russian drones strike dwellings in Ukraine's Kharkiv, several injured

Russian drones strike dwellings in Ukraine’s Kharkiv, several injured

June 5, 2025
Kirk delivers walkoff hit as Jays edge Phillies

Kirk delivers walkoff hit as Jays edge Phillies

June 5, 2025

Recent News

15-year-old, pinned by car, is killed at SoCal high school

15-year-old, pinned by car, is killed at SoCal high school

June 5, 2025
3
Harvard foreign student visas targeted in Trump administration proclamation

Harvard foreign student visas targeted in Trump administration proclamation

June 5, 2025
4
Russian drones strike dwellings in Ukraine's Kharkiv, several injured

Russian drones strike dwellings in Ukraine’s Kharkiv, several injured

June 5, 2025
4
Kirk delivers walkoff hit as Jays edge Phillies

Kirk delivers walkoff hit as Jays edge Phillies

June 5, 2025
6

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

15-year-old, pinned by car, is killed at SoCal high school

15-year-old, pinned by car, is killed at SoCal high school

June 5, 2025
Harvard foreign student visas targeted in Trump administration proclamation

Harvard foreign student visas targeted in Trump administration proclamation

June 5, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co